Trial reportAmyotrophic lateral sclerosis & frontotemporal degeneration2016
Patient-reported problematic symptoms in an ALS treatment trial.
Trial report in Amyotrophic lateral sclerosis & frontotemporal degeneration, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05328492 (Volume Targeted Versus Pressure Targeted Non-invasive Ventilation in Amyotrophic Lateral Sclerosis), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Volume Targeted Versus Pressure Targeted Non-invasive Ventilation in Amyotrophic Lateral Sclerosis: a Randomised Control Trial.
Who cites it
19 citing papers in PubMed, 49 citations in OpenAlex.
- Response to: Comment on 'The Values and Preferences of People Living With Motor Neurone Disease (MND): A Systematic Review and Meta-Analysis'.Clinical and public health guidelines · 2026Article
- Comment on 'The Values and Preferences of People Living With Motor Neurone Disease (MND): A Systematic Review and Meta-Analysis'.Clinical and public health guidelines · 2026Article
- The Values and Preferences of People Living With Motor Neurone Disease (MND): A Systematic Review and Meta-Analysis.Clinical and public health guidelines · 2026Article
- Clinical evaluation of communication brain computer interfaces in amyotrophic lateral sclerosis: a landscape analysis.Frontiers in human neuroscience · 2026Article
- Exploring mechanisms of behavior change for healthcare professionals in cough and secretion management in ALS.Neurodegenerative disease management · 2025Article
- Health-Related Quality of Life, Psychological Health, and Patient-Reported Outcomes of Amyotrophic Lateral Sclerosis Patients in China.Brain sciences · 2025Article
- The experience of pain symptoms in patients with amyotrophic lateral sclerosis: a qualitative study.Scientific reports · 2025Article
- Non-motor symptoms in patients with amyotrophic lateral sclerosis: current state and future directions.Journal of neurology · 2024Review
- Non-motor symptoms in motor neuron disease: prevalence, assessment and impact.Brain communications · 2024Article
- Pain in amyotrophic lateral sclerosis: a narrative review.Journal of Yeungnam medical science · 2022Article
- Face and content validation of the amyotrophic lateral sclerosis-Bulbar dysfunction index (ALS-BDI).Frontiers in neurology · 2022Article
- Ultrasound-guided glenohumeral joint injections for shoulder pain in ALS: A case series.Frontiers in neurology · 2022Article
- Validation of Articulatory Rate and Imprecision Judgments in Speech of Individuals With Amyotrophic Lateral Sclerosis.American journal of speech-language pathology · 2021Article
- Validating the Persian version of the amyotrophic lateral sclerosis-specific quality of life-revised instrument.Current journal of neurology · 2021Article
- Sleep and Sleep Disruption in Amyotrophic Lateral Sclerosis.Current neurology and neuroscience reports · 2020Review
- The Prevalence and Management of Saliva Problems in Motor Neuron Disease: A 4-Year Analysis of the Scottish Motor Neuron Disease Register.Neuro-degenerative diseases · 2020Article
- Sleep disturbances in patients with amyotrophic lateral sclerosis: current perspectives.Nature and science of sleep · 2019Article
- Symptom management in amyotrophic lateral sclerosis: We can do better.Muscle & nerve · 2018Article
- Sleep and Survival in Amyotrophic Lateral Sclerosis (ALS): The Parallelism in Motor and Non-Motor Progression.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
This study was undertaken to determine which symptoms are perceived to be most problematic for patients with ALS and how their severity changes over time. A retrospective study was performed of data from a randomized, double-blind, placebo-controlled trial of ceftriaxone in ALS. Participants completed the ALS Specific Quality of Life Instrument (ALSSQoL) at baseline and at intervals up to 96 weeks. Ten ALSSQoL items ask participants to rate how problematic symptoms are (the subjective feeling of burden of these symptoms), ranging from 0 (no problem) to 10 (tremendous problem). Six are non-bulbar (pain, fatigue, breathing, strength and ability to move, sleep, and bowel and bladder) and four are bulbar (eating, speaking, excessive saliva, and mucus). Results revealed that there were 82 subjects (56% males, mean age 53 ± 10.3 years) with ALSSQoL data for weeks 0 and 96. All 10 symptoms became more problematic over time. For non-bulbar symptoms, strength/ability to move and fatigue were the most problematic. Speaking was the most problematic bulbar symptom. In conclusion, although all the symptoms in the ALSSQoL were acknowledged as problematic, some had greater impact than others. All became more problematic over time. This should help prioritize research into symptom management, and assist individual clinicians in their approach to patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.